Association of total bilirubin and indirect bilirubin content with metabolic syndrome among Kazakhs in Xinjiang
Tóm tắt
Some studies have shown that a high level of bilirubin is a protective factor against metabolic syndrome (MS), while a high level of transaminase is a risk factor for MS. However, the existing results are inconsistent and few cohort studies have been published. Using an ambispective cohort study, 565 Kazakhs from Xinjiang, China were selected as the study subjects. The baseline serum bilirubin and transaminase levels of the subjects were divided into quartiles and the relationship between these values and the incidence of MS was analyzed. The definition of MS was based on the Joint Interim Statement (JIS) diagnostic criteria. The average follow-up time for the subjects was 5.72 years. The cumulative incidence of MS was 36.11% (204 of the 565 subjects), and the incidence density was 63.10/1000 person-years. Multivariate Cox regression analysis showed that the levels of total bilirubin (TBIL) and indirect bilirubin (IBIL) were negatively correlated with the occurrence of MS, Compared to the lowest quartile level (Q1), the hazard ratios of MS the TBIL levels at the Q2-Q4 quartiles were: 0.47 (0.31–0.71), 0.53 (0.35–0.79), and 0.48 (0.32–0.72), respectively, while IBIL levels at the Q2-Q4 quartiles showed an MS hazard ratio of 0.48 (0.32–0.72), 0.54(0.36–0.81), and 0.52 (0.35–0.77), respectively, all at a 95% confidence level. However, no relationship was found between transaminase levels and the incidence of MS. Serum TBIL and IBIL levels were negatively correlated with the incidence of MS in a Kazakh population in China.
Tài liệu tham khảo
Mendrick DL, Diehl AM, Topor LS, et al. Metabolic syndrome and associated diseases: from the bench to the clinic. Toxicol Sci. 2018;162(1):36–42.
Vona R, Gambardella L, Cittadini C, et al. Biomarkers of oxidative stress in metabolic syndrome and associated diseases. Oxidative Med Cell Longev. 2019;2019:8267234.
Mccracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin Dermatol. 2018;36(1):14–20.
Cheriyath P, Gorrepati VS, Peters I, et al. High Total Bilirubin as a Protective Factor for Diabetes Mellitus: An Analysis of NHANES Data From 1999–2006. J Clin Med Res. 2010;2(5):201–6.
Wagner KH, Wallner M, Molzer C, et al. Looking to the horizon: the role of bilirubin in the development and prevention of age-related chronic diseases. Clin Sci (Lond). 2015;129(1):1–25.
Wang S, Zhang J, Zhu L, et al. Association between liver function and metabolic syndrome in Chinese men and women. Sci Rep. 2017;7:44844.
Shiraishi M, Tanaka M, Okada H, et al. Potential impact of the joint association of total bilirubin and gamma-glutamyltransferase with metabolic syndrome. Diabetol Metab Syndr. 2019;11:12.
Schindhelm RK, Dekker JM, Nijpels G, et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn study. Atherosclerosis. 2007;191(2):391–6.
Lee SH, Cho DY, Joo NS, et al. The relationship of alanine aminotransferase to metabolic syndrome in a Korean population. Turk J Gastroenterol. 2018;29(1):52–60.
Pei D, Hsia TL, Chao TT, et al. Gamma-glutamyl transpeptidase in men and alanine aminotransferase in women are the most suitable parameters among liver function tests for the prediction of metabolic syndrome in nonviral hepatitis and nonfatty liver in the elderly. Saudi J Gastroenterol. 2015;21(3):158–64.
Zhang XH, Zhang M, He J, et al. Comparison of anthropometric and Atherogenic indices as screening tools of metabolic syndrome in the Kazakh adult population in Xinjiang. Int J Environ Res Public Health. 2016;13(4):428.
Guo SX, Zhang XH, Zhang JY, et al. Visceral adiposity and anthropometric indicators as screening tools of metabolic syndrome among low income rural adults in Xinjiang. Sci Rep. 2016;6:36091.
Heng G, Rulin M, Jingyu Z, Dongsheng R, Shangzhi X, Feng S, Shuxia G. Comparison and analysis of epidemic characteristics of metabolic syndrome between Kazakh and Han ethnic groups in Xinjiang. Chin J Hypertension. 2011;19(06):538–43.
Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; world heart federation; international atherosclerosis society; and International Association for the Study of obesity. Circulation. 2009;120(16):1640–5.
Sun H, Liu Q, Wang X, et al. The longitudinal increments of serum alanine aminotransferase increased the incidence risk of metabolic syndrome: a large cohort population in China. Clin Chim Acta. 2019;488:242–7.
Hwang JH, Kam S, Shin JY, et al. Incidence of metabolic syndrome and relative importance of five components as a predictor of metabolic syndrome: 5-year follow-up study in Korea. J Korean Med Sci. 2013;28(12):1768–73.
Vitek L. The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Front Pharmacol. 2012;3:55.
Bulmer AC, Verkade HJ, Wagner KH. Bilirubin and beyond: a review of lipid status in Gilbert's syndrome and its relevance to cardiovascular disease protection. Prog Lipid Res. 2013;52(2):193–205.
Boon AC, Bulmer AC, Coombes JS, Fassett RG. Circulating bilirubin and defense against kidney disease and cardiovascular mortality: mechanisms contributing to protection in clinical investigations. Am J Physiol Renal Physiol. 2014;307(2):123–36.
Gazzin S, Vitek L, Watchko J, et al. A novel perspective on the biology of bilirubin in health and disease. Trends Mol Med. 2016;22(9):758–68.
Neuzil J, Stocker R. Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J Biol Chem. 1994;269(24):16712–9.
Wu TW, Fung KP, Yang CC. Unconjugated bilirubin inhibits the oxidation of human low density lipoprotein better than Trolox. Life Sci. 1994;54(25):477–P481.
Peng YF, Xie LQ, Xiang Y, et al. Serum bilirubin and their association with C-reactive protein in patients with migraine. J Clin Lab Anal. 2016;30(6):982–5.
Zhao X, Li L, Li X, et al. The relationship between serum bilirubin and inflammatory bowel disease. Mediat Inflamm. 2019;2019:5256460.
Mazzone GL, Rigato I, Ostrow JD, et al. Bilirubin inhibits the TNFalpha-related induction of three endothelial adhesion molecules. Biochem Biophys Res Commun. 2009;386(2):338–44.
Takei R, Inoue T, Sonoda N, et al. Bilirubin reduces visceral obesity and insulin resistance by suppression of inflammatory cytokines. PLoS One. 2019;14(10):e223302.
Dong H, Huang H, Yun X, et al. Bilirubin increases insulin sensitivity in leptin-receptor deficient and diet-induced obese mice through suppression of ER stress and chronic inflammation. Endocrinology. 2014;155(3):818–28.
Huang SS, Chan WL, Leu HB, et al. Serum bilirubin levels predict future development of metabolic syndrome in healthy middle-aged nonsmoking men. Am J Med. 2015;128(10):1135–8.
Kawamoto R, Kikuchi A, Akase T, et al. Total bilirubin independently predicts incident metabolic syndrome among community-dwelling women. Diabetes Metab Syndr. 2019;13(2):1329–34.
Oda E, Aizawa Y. Total bilirubin is inversely associated with metabolic syndrome but not a risk factor for metabolic syndrome in Japanese men and women. Acta Diabetol. 2013;50(3):417–22.
Li XH, Lin HY, Guan LY, et al. Direct bilirubin levels and risk of metabolic syndrome in healthy Chinese men. Biomed Res Int. 2017;2017:9621615.
Maruhashi T, Soga J, Fujimura N, et al. Hyperbilirubinemia, augmentation of endothelial function, and decrease in oxidative stress in Gilbert syndrome. Circulation. 2012;126(5):598–603.
Sundararaghavan VL, Binepal S, Stec DE, et al. Bilirubin, a new therapeutic for kidney transplant? Transplant Rev (Orlando). 2018;32(4):234–40.
Zhou JA, Jiang M, Yang X, et al. Unconjugated bilirubin ameliorates the inflammation and digestive protease increase in TNBS-induced colitis. Mol Med Rep. 2017;16(2):1779–84.
Boon AC, Hawkins CL, Coombes JS, et al. Bilirubin scavenges chloramines and inhibits myeloperoxidase-induced protein/lipid oxidation in physiologically relevant hyperbilirubinemic serum. Free Radic Biol Med. 2015;86:259–68.
McCarty MF. “Iatrogenic Gilbert syndrome”--a strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin. Med Hypotheses. 2007;69(5):974–94.
Lin JP, Vitek L, Schwertner HA. Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clin Chem. 2010;56(10):1535–43.